The stock’s average analyst target price of $17.50 suggests upside potential of 446% over the next 12 months. The high price target estimate stands at $25. TScan Therapeutics is a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback